These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24071445)

  • 21. Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
    Fushimi N; Fujikura H; Shiohara H; Teranishi H; Shimizu K; Yonekubo S; Ohno K; Miyagi T; Itoh F; Shibazaki T; Tomae M; Ishikawa-Takemura Y; Nakabayashi T; Kamada N; Ozawa T; Kobayashi S; Isaji M
    Bioorg Med Chem; 2012 Nov; 20(22):6598-612. PubMed ID: 23062824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
    Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
    Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
    Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
    Lee SH; Kim MJ; Lee SH; Kim J; Park HJ; Lee J
    Eur J Med Chem; 2011 Jul; 46(7):2662-75. PubMed ID: 21514014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Scalable Synthesis of Tofogliflozin.
    Ohtake Y; Emura T; Nishimoto M; Takano K; Yamamoto K; Tsuchiya S; Yeu SY; Kito Y; Kimura N; Takeda S; Tsukazaki M; Murakata M; Sato T
    J Org Chem; 2016 Mar; 81(5):2148-53. PubMed ID: 26871504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
    Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
    Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
    Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
    Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
    Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
    Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
    J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a β-glycopyranoside.
    Wang XJ; Zhang L; Byrne D; Nummy L; Weber D; Krishnamurthy D; Yee N; Senanayake CH
    Org Lett; 2014 Aug; 16(16):4090-3. PubMed ID: 25061799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
    Hummel CS; Lu C; Loo DD; Hirayama BA; Voss AA; Wright EM
    Am J Physiol Cell Physiol; 2011 Jan; 300(1):C14-21. PubMed ID: 20980548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
    Yamane M; Kawashima K; Yamaguchi K; Nagao S; Sato M; Suzuki M; Honda K; Hagita H; Kuhlmann O; Poirier A; Fowler S; Funk C; Simon S; Aso Y; Ikeda S; Ishigai M
    Xenobiotica; 2015 Mar; 45(3):230-8. PubMed ID: 25350082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional effects of glucose transporters in human ventricular myocardium.
    von Lewinski D; Gasser R; Rainer PP; Huber MS; Wilhelm B; Roessl U; Haas T; Wasler A; Grimm M; Bisping E; Pieske B
    Eur J Heart Fail; 2010 Feb; 12(2):106-13. PubMed ID: 20083620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
    Zhao X; Sun B; Zheng H; Liu J; Qian L; Wang X; Lou H
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2201-2205. PubMed ID: 29764742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
    Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense.
    Morita H; Deguchi J; Motegi Y; Sato S; Aoyama C; Takeo J; Shiro M; Hirasawa Y
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1070-4. PubMed ID: 20036535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.